date:Jun 12, 2014
PURE Bioscience, creator of the patented silver dihydrogen citrate (SDC) antimicrobial, reported financial results for the second fiscal quarter ended April 30, 2014.
Revenues for the third fiscal quarter of 2014 were $261,000, compared with revenues of $258,000 for the third fiscal quarter of 2013. Total operating costs and expenses, excluding share-based compensation, other share-based expenses, and restructuring costs, for the third fiscal quarter of 2014 and 2013, were $1.7 million, and $1.